statins

systematic review meta-analysis network meta-analysis

Select cardiovascular preventionheart failurepercutaneous coronary intervention All type of patientDiabetic patientsuncoded clinical condition ***primary preventionpatients with prior MI or with CHD       dietpretreatment with statinstatinsstatins high dose atorvastatincerivastatinfluvastatinlovastatinpravastatinrosuvastatinsimvastatin vs placebo or controlvs angioplastyvs ezetimibevs statin       cerebral vascular diseaseelderlyhypertensive patientstype 2 diabetes

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (59)stroke (fatal and non fatal) (33)Coronary death (30)Non fatal MI (29)Coronary event (28)non cardiovascular death (27)Cardiovascular death (25)Rhabdomyolysis (23)cardiovascular events (20)Coronary death and non fatal MI (18)MACE (17)cardiac death (14)Fatal stroke (14)new-onset diabetes (14)Death from cancer (11)Myopathy (10)Haemmorhagic stroke (9)Adverse events (6)Revascularization (5)Fatal MI (2)Non vascular death (2)MI (CK-MB >3x ULN at 6 and 12 hours after PCI) (1)MI (troponin I >3x ULN at 6 and 12 hours after PCI) (1)Venous thromboembolism (1)Cancer (1)Non fatal stroke (1)myocardial infarction (fatal and non fatal) (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	stroke (fatal and non fatal)
cardiovascular prevention
atorvastatin
Mohler, 2003	atorvastatin	placebo	secondary prevention		Low risk of bias	-
ASCOT, 2003	atorvastatin	placebo	at risk hypertensive	hypertensive patients	Low risk of bias	conclusive
ASPEN, 2006	atorvastatin	placebo	diabetic	type 2 diabetes	Low risk of bias	negative
CARDS, 2004      NCT	atorvastatin	placebo	diabetic	type 2 diabetes	Low risk of bias	conclusive
GREACE, 2002	atorvastatin	usual care	secondary prevention		Risk of bias	suggesting
AVERT, 1999	atorvastatin high dose	angioplasty	secondary prevention		Risk of bias	negative
TNT, 2005            NCT	atorvastatin high dose	atorvastatin	secondary prevention		Low risk of bias	conclusive
Vascular basis, 2005	atorvastatin high dose	lovastatin	secondary prevention		Exploratory	negative
SAGE, 2007	atorvastatin high dose	pravastatin	secondary prevention		Exploratory	suggesting
REVERSAL, 2004	atorvastatin high dose	pravastatin	secondary prevention		Exploratory	negative
IDEAL, 2005        NCT	atorvastatin high dose	simvastatin	secondary prevention		Risk of bias	suggesting
fluvastatin
FLARE, 1999	fluvastatin	placebo	secondary prevention		Exploratory	negative
LCAS, 1997	fluvastatin	placebo	secondary prevention		Exploratory	negative
HYRIM, 2005	fluvastatin	placebo	hypertensive	hypertensive patients	Exploratory	negative
Riegger et al., 1999	fluvastatin	placebo	secondary prevention		Low risk of bias	negative
BCAPS, 2001	fluvastatin	placebo	primary prevention	cerebral vascular disease	Low risk of bias	negative
LIPS, 2002	fluvastatin	placebo	secondary prevention		Low risk of bias	suggesting
lovastatin
Weintraub, 1994	lovastatin	placebo	secondary prevention		Low risk of bias	negative
CRISP 40mg, 1994    NCT	lovastatin	placebo	diabetic		Exploratory	-
CRISP 20mg, 1994    NCT	lovastatin	placebo	diabetic		Exploratory	-
ACAPS, 1994    NCT	lovastatin	placebo	secondary prevention	cerebral vascular disease	Exploratory	suggesting
MARS, 1993      NCT	lovastatin	placebo	secondary prevention		Exploratory	negative
CCAIT, 1994	lovastatin	placebo	secondary prevention		Exploratory	negative
AFCAPS/TexCAPS, 1998	lovastatin	placebo	primary prevention		Low risk of bias	conclusive
CLAPT, 1999	lovastatin	usual care	secondary prevention		Exploratory	negative
Sahni, 1991	lovastatin	usual care	secondary prevention		Risk of bias	negative
pravastatin
FAST Fukuoka pravastatin, 2002	pravastatin	control	primary prevention		Exploratory	-
MEGA, 2006        NCT	pravastatin	control	primary prevention		Risk of bias	suggesting
WOSCOPS, 1995	pravastatin	placebo	primary prevention		Low risk of bias	conclusive
REGRESS, 1995	pravastatin	placebo	secondary prevention		Exploratory	suggesting
PLAC II, 1995	pravastatin	placebo	secondary prevention		Exploratory	negative
LIPID, 1998	pravastatin	placebo	secondary prevention		Low risk of bias	conclusive
CARE, 1996	pravastatin	placebo	secondary prevention		Low risk of bias	conclusive
PACT, 2004	pravastatin	placebo	secondary prevention		Low risk of bias	negative
PROSPER (primary prevention subgroup), 2002	pravastatin	placebo	primary prevention	elderly	Exploratory	negative
CAIUS, 1996	pravastatin	placebo	primary prevention	cerebral vascular disease	Exploratory	negative
PROSPER, 2002	pravastatin	placebo	secondary prevention	elderly	Low risk of bias	conclusive
PHYLLIS, 2004	pravastatin	placebo	diabetic	cerebral vascular disease hypertensive patients	Exploratory	-
PMSG, 1993	pravastatin	placebo	primary prevention		Exploratory	negative
PLAC I, 1995	pravastatin	placebo	secondary prevention		Exploratory	suggesting
KLIS, 2000	pravastatin	usual care	primary prevention		Risk of bias	-
GISSI Prevenzione, 2000	pravastatin	usual care	secondary prevention		Risk of bias	negative
ALLHAT, 2002      NCT	pravastatin	usual care	at risk hypertensive	hypertensive patients	Risk of bias	negative
rosuvastatin
HOPE 3, 2016      NCT	rosuvastatin	placebo	primary prevention		Low risk of bias	conclusive
METEOR, 2007      NCT	rosuvastatin	placebo	diabetic		Exploratory	negative
JUPITER, 2008    NCT	rosuvastatin	placebo	primary prevention		Low risk of bias	conclusive
simvastatin
4S, 1994	simvastatin	placebo	secondary prevention		Low risk of bias	conclusive
MAAS, 1994	simvastatin	placebo	secondary prevention		Exploratory	negative
CIS, 1997	simvastatin	placebo	secondary prevention		Exploratory	negative
HPS (diabetic primary prevention sub group), 2003	simvastatin	placebo	diabetic	type 2 diabetes	Exploratory	-
HPS, 2002	simvastatin	placebo	secondary prevention		Low risk of bias	conclusive
SEARCH, 2010    NCT	simvastatin high dose	simvastatin	secondary prevention		Low risk of bias	suggesting
heart failure
atorvastatin
Yamada, 2007	atorvastatin	control	heart failure			negative
Wojnicz, 2006	atorvastatin	control	heart failure			negative
Strey, 2005	atorvastatin	placebo	heart failure			-
Sola, 2006	atorvastatin	placebo	heart failure		Low risk of bias	negative
cerivastatin
Laufs, 2004	cerivastatin	placebo	heart failure		Low risk of bias	-
rosuvastatin
CORONA, 2007      NCT	rosuvastatin	placebo	heart failure		Low risk of bias	negative
Krum, 2007	rosuvastatin	placebo	heart failure		Low risk of bias	negative
GISSI-HF rosuvastatine, 2008      NCT	rosuvastatin	placebo	heart failure		Low risk of bias	negative
simvastatin
Hong, 2005	simvastatin	control	heart failure		Risk of bias	negative
Node, 2003	simvastatin	placebo	heart failure			negative
Landmesser, 2005	simvastatin	ezetimibe	heart failure			-
percutaneous coronary intervention
atorvastatin
NAPLES II (Briguori), 2009	atorvastatin	control				suggesting
ARMYDA, 2004	atorvastatin	placebo			Low risk of bias	suggesting
ARMYDA-RECAPTURE, 2009	atorvastatin reload	placebo			Low risk of bias	suggesting
GAIN, 2001	atorvastatin	usual care				negative
fluvastatin
FLARE, 1999	fluvastatin	placebo			Low risk of bias	negative
LIPS, 2002	fluvastatin	placebo			Low risk of bias	negative
pravastatin
PREDICT, 1997	pravastatin	placebo			Low risk of bias	negative